CELLINK Bioprinting will be the anchor tenant of the building which is strategically located in expansive Kallebäck in central Gothenburg. The newly built property will provide seamless integration in premises that are adapted to the company’s specific needs and will accommodate all parts of the production chain as well as offices and meeting areas for the company’s administrative staff.

We look forward to bringing together all Swedish parts of the Bioprinting business to new and sustainable premises. This means that we can contribute to establish this strategic location in Gothenburg as an innovation hub for bioconvergence and life science. We are currently on an exciting growth journey where co-location of large parts of the business in one place feels important – this will be a place where we can grow and thrive together!” says Cecilia Edebo, Managing Director CELLINK Bioprinting.

The property has a clear focus on sustainability with solar cells on the roof, which means that the building is self-sufficient by renewable energy. Sustainability is important for CELLINK Bioprinting and the new building is in line with the company’s sustainability agenda. Entré Kallebäck is built to meet the requirements for certification according to Green Building.

Rendering by Liljewall Arkitekter and sketch by GAJD Arkitekter.

For more information please contact:
Cecilia Edebo, Managing Director CELLINK Bioprinting  
Phone: +46 (0)70 511 05 90
E-mail: ced@cellink.com  

Isabelle Ljunggren, Head of Communications CELLINK
Phone: +46 (0)70 830 08 90
E-mail: il@cellink.com

This is information that CELLINK AB (publ) submitted for publication, through the agency of the contact persons set out above, on May 24, 2021 at 08:00 (CEST).

Founded in 2016, CELLINK is the leading bioconvergence company in world that provides technologies, products, and services to create, understand and master biology. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. CELLINK’s products are trusted by more than 2,000 laboratories, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 1,700 publications. CELLINK is creating the future of medicine. CELLINK is listed on the Nasdaq the Stockholm under CLNK B. www.cellink.com/investors